Physicians' Academy for Cardiovascular Education
Continuous direct factor Xa inhibitor therapy with apixaban was a safe and effective anticoagulation alternative in patients at risk of stroke undergoing atrial fibrillation catheter ablation.
Longer total time spent in AF was associated with a higher risk of thromboembolism and ischemic stroke in adults with paroxysmal AF, who were not on anticoagulation, independent of known stroke risk factors.
Dr. Kotecha explains how the pathophysiologies of HFpEF and atrial fibrillation are interconnected, and what this means for management of patients with both conditions.
A prospective study showed an inversed association between nut consumption and incidence of atrial fibrillation and heart failure in the Swedish population.
ESC HF 2018 The second part of the Grand Debate on Drugs or interventions focused on the value of catheter ablation in comparison to drug for treatment of patients with both AF and HF.
In a retrospective analysis of a healthcare cost and utilization database, cannabis use was associated with a lower AF risk in hospitalized heart failure patients.
This conversation covers differences in efficacy and safety outcomes of treatment with DOACs or VKA, and how to decide what to give to whom and for how long, in light of the risk of antithrombotic and bleeding complications.
In the AXAFA-AFNET 5 trial, continuous apixaban therapy was non-inferior to continuous VKA treatment in terms of stroke, bleedings, cognitive function and MRI-detected acute brain lesions.
Incident atrial fibrillation (AF) is associated with both greater cognitive decline and increased risk of dementia compared with individuals without AF, independent of clinical ischemic stroke.
Four Heart Rhythm Societies have composed a consensus statement on how to prevent, assess and treat cognitive decline in atrial fibrillation and other arrhythmias.
The European Heart Rhythm Association (EHRA) updated its practical guide on use of non-vitamin K antagonist oral anticoagulants in specific clinical situations and particular patient groups.
New data of the ongoing GLORIA-AF registry on use of dabigatran in AF show low rates of major bleeding and stroke, and long-term safety data are consistent with other real-world and RCT evidence.